blood pressure, and was well tolerated. These data  suggest that exenatide monotherapy may provide a  viable treatment option beyond diet and exercise and  support further study of exenatide monotherapy in  patients with type 2 diabetes naive to treatment with  antidiabetic agents.  ACKNOWLEDGM ENTS  This research was financially supported by Amylin  Pharmaceuticals, Inc., San Diego, California, and Eli  Lilly and Company, Indianapolis, Indiana. Publication  was financially supported by Eli Lilly and Company.  Dentil R. Milton, MS, provided the primary statisti-  cal support for this manuscript. Hangtao Xu, MS, and  Jude Burger, MS, of Eli Lilly and Company, provided  additional statistical support.  Dr. Moretto has no conflicts of interest to declare.  Ms. Milton and Drs. Wolka and Brodows are employ-  ees and shareholders of Eli Lilly and Company. Mr.  Ridge has been a member of the speaker's bureaus at  Amylin Pharmaceuticals, Inc. and Eli Lilly and Com-